A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients

Goldberg, Anne C.; Dunbar, Richard L.; Hemphill, Linda; Babirak, Stephan P.; Wilson, Gerald S.; Wooten, Michael; Iydroose, Mohamed; Dacus, Kelley C; Minchew, Heather; Dutton, Julie Ann; Moriarty, Patrick M.

doi:10.1016/j.jacl.2020.08.005

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Терапия алирокумабом, по данным исследования ODYSSEY OUTCOMES, способствовала снижению ХС ЛНП (после исключения пациентов, прервавших преждевременно терапию) по сравнению с плацебо на 62,7% -через 4 мес, на 61,0% -через 12 мес и на 54,7% -через 48 мес [5]. Продемонстрирована высокая гиполипидемическая активность как у пациентов с СГХС, так и без нее [7][8][9].…”

Section: Discussionunclassified

Efficacy and safety of the use of alirocumab in real clinical practice

Korneva

Kuznetsova

Egorova

et al. 2023

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To evaluate the results of two-year use of alirokumab in Karelia Republic. Materials and methods. The observation group consisted of 27 patients (17 patients with familial hypercholesterolemia, 10 patients with the history of myocardial infarction), mean age 53.44.3 years, 70.3% men, follow-up duration from one year to 2.5 years, 18 (66.6%) patients received therapy for more than 2 years. 19 patients received alirocumab at a dose of 75 mg/ml once every 2 weeks, eight at a dose of 150 mg/ml once every 2 weeks. Before the start of therapy, the majority received maximally tolerated statin therapy, 10 patients received statin therapy in combination with ezetemibe, 3 patients received ezetemibe monotherapy due to statin intolerance. The target levels of LDL cholesterol were considered for very high risk patients less than 1.4 mmol/L, high risk less than 1.8 mmol/L, extreme risk less than 1 mmol/L. Results. The reduction of LDL on therapy with alirocumab was 58%; target levels of LDL were achieved in 77.8%. The level of decrease in LDL cholesterol less than 50% was noted only in 7.4% of cases. Patients requiring a large dose of the drug were classified as very high risk, had higher cholesterol and LDL-C levels. The level of Lp(a) decrease on 29.7% by 612 months. No destabilization of coronary heart disease, new cases of stroke were registered. Conclusion. The inclusion of alirocumab in the treatment regimen contributed to the stable course of atherosclerosis-associated diseases, the achievement of LDL cholesterol targets in 77.8% of patients, was not accompanied by side effects during 2.5 years therapy.

show abstract

Section: Discussionunclassified

Efficacy and safety of the use of alirocumab in real clinical practice

Korneva

Kuznetsova

Egorova

et al. 2023

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

Connelly‐Smith

Alquist

Aqui

et al. 2023

J of Clinical Apheresis

218

View full text Add to dashboard Cite

The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence-based use of therapeutic apheresis (TA) in human disease. In the Ninth Edition, the JCA Special Issue Writing Committee has incorporated systematic review and evidence-based approaches in the grading of evidence and categorization of apheresis indications to make recommendations on the use of apheresis in a wide variety of diseases and conditions. This edition has largely maintained the general layout and concept of a fact sheet introduced in the Fourth Edition (2007). Each fact sheet succinctly summarizes the evidence for the use of TA in a specific disease or medical condition. The Ninth Edition of the JCA Special Issue comprises 91 fact sheets and

show abstract